anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Coordination of respiration, heart rate and swallowing in preterm and term neonates has been subject of various studies in the past; its impeccable functioning is a key criterion to be fulfilled before infants are discharged home from the NICU. Whether coordination abilities depend only on gestational age and how they can be diagnosed objectively remains controversial. Also, the ideal time point of starting to introduce suck feeds and to challenge coordination of breathing and swallowing is unknown and largely remains a matter of trial and error with the risk of causing iatrogenic aspirations of milk if babies are not ready for suck feeds. Successful coordination of swallowing and breathing is generally considered as a higher neurological function and it does represent a mile stone in overall child development. Therefore, measurement of its level of functioning could have the potential to serve as a predictor for neurological outcome. However, it is yet unknown to what extent difficulties in preterm infants allow predictions concerning their neurological development and future outcome. One of the major reasons for these unsolved questions lies in the lack of diagnostic tools to objectively measure suck-swallow-breathing coordination with sufficient accuracy, which make a precise analysis of coordination patterns in preterm infants almost impossible. Considering the relevance of these questions, it seems important to develop tools to observe coordination of breathing, heart rate and swallowing in neonates with possibly greater accuracy.

In this single-centre pilot study 15 preterm infants of 32 to 42 weeks gestational age will be included. Transesophageal ECG and EMG signals will be measured using an Edi-gastric tube (Maquet, Getinge Group, Solna Sweden), a CE-certified neonatal gastric tube equipped with electrodes. Due to the proximity of the esophageal electrodes within the gastric tube to the heart and diaphragm, esophageal ECG and EMG signals can be acquired and are probably less susceptible to motion artefacts of the baby than the commonly used skin electrodes. This is well known from measurements in adults. Moreover, motion of esophageal electrodes due to peristalsis, respiration and cardiac motion superimposes the ECG as baseline wander and might be a surrogate for the coordination abilities of preterm infants.

Using these novel esophageal data this study's goal is to obtain objective data representing maturational patterns of breathing, heart rate, and swallowing in preterm infants. Possibly derived coordination patterns might help to guide nurses and clinicians to introduce suck feeds and to develop specific early intervention strategies. Furthermore, if the gastric tube-EMG proves to be accessible in real time, it could potentially replace standard monitoring tools that require the use of skin electrodes in the future. This would not only facilitate nursing and preserve skin integrity but also simplify bonding between the parents and their infants in the NICU.
Participant's bladder is backfilled with 50 mL of 1% lidocaine for 15 minutes, then drained prior to procedure start. Dose of 100 units onabotulinumtoxin A with dilution to 100 Units/10 mL with preservative-free 0.9% Sodium Chloride Injection is prepared. Cystoscopy is performed. The 23 gauge Laborie InjeTAK needle is inserted 3 mm into the detrusor. 5 injections of 2 mL each (total volume of 10 mL) in a single procedure is performed 1 cm apart in the bladder body. For the final injection, approximately 1 mL of sterile normal saline should be injected such that the remaining onabotulinumtoxin A in the needle is delivered to the bladder.
The present invention relates to botanical hair-dyeing compositions and hair-dyeing methods using the same. Disclosed are hair-dyeing compositions comprising tannic acid or haematoxylin (or hematine), water-soluble iron salts, and/or D, L-cysteine and/or its salts, derivatives of D, L-cysteine, and/or thioglycolic acid and/or its salts or ester. The botanical hair-dyeing compositions are made into a two-solution-type form of black and brown color hair dye or into a three-solution-type form of black color hair dye. The hair-dyeing method of applying the hair-dyeing composition of two-solution-type form comprises the steps of (1) applying onto partially wet or dry hair for a sufficient time a first solution comprising a water-soluble iron salt or its mixture with one or more suitable excipients, and then washing out the first solution with water, and (2) applying onto the partially wet or dry hair treated with said step (1) for a sufficient time a second solution comprising tannic acid or haematoxylin (or hematine) or its mixture with one or more suitable excipients, and then washing out the second solution with water, and drying the dyed hair. The hair-dyeing method of applying the hair-dyeing composition of three-solution-type form comprises the steps of (1) applying onto partially wet or dry hair for a sufficient time a first solution comprising D, L-cysteine and/or its salts, derivatives of D, L-cysteine, and/or thioglycolic acid and/or its salts or ester, or its mixture with one or more suitable excipients, and then washing out the first solution with water, and (2) applying onto the partially wet or dry hair treated with said step (1) for a sufficient time a second solution comprising a water-soluble iron salt or its mixture with one or more suitable excipients, and then washing out the second solution with water, and (3) applying onto the partially wet or dry hair treated with said step (2) for a sufficient time a third solution comprising tannic acid or haematoxylin (or hematine) or its mixture with one or more suitable excipients, and then washing out the third solution with water, and drying the dyed hair. The present invention provides safe, non-oxidizing hair-dyeing compositions and hair-dyeing methods using the same, which do not induce dermal irritation, skin allergy or genotoxicity, nor damage the hair, and also exhibit excellent black or brown dyeing capability, resulting in excellent color tone and color fastness. The dyed hair is not faded even after shampooling.
The invention relates to an oncolytic virus Ad-TD-hIL12 for targeted treatment of human tumors and an application thereof. The virus is preserved in China Center for Type Culture Collection with a preservation number of CCTCC NO: V201031. The carrier of the virus is C-subtype 5-type adenovirus Ad5 with three genes (E1A-CR2, E1B19K and E3gp-19K) deleted and E3gp-19K promoter used to express p35 and p40 subunit gene sequences of human IL12. The virus can reproduce dissolved tumor cells in tumor cells by infecting the tumor cells and generate high-level hIL12 with multiple anti-tumor functions in tumor tissues. The hIL12 has the function of resisting tumor angiogenesis, can adjust immuno competence of a human body, enables an organism to generate anti-tumor specific immunity capacity, kills distant metastatic tumor cells and prevents tumor reoccurrence. As a result, the hIL 12 can serve as a targeted genetic engineering medicament for treating various solid tumors, can not only be applied to tumor intrathecal injection but also applied to enterocoelia and chest intrathecal injection without triggering obvious side-effects, thus achieving good curative effects and security.
INTRODUCTION: In cases of metastatic and unresectable urothelial carcinoma with no disease progression after 4 cycles of chemotherapy, including platinum agents, treatment options include continuation of chemotherapy or switching to maintenance therapy with avelumab. This study compared the treatment outcomes of avelumab maintenance therapy with those of pembrolizumab in urothelial carcinoma using propensity score matching.
PATIENTS AND METHODS: Between January 2017 and December 2022, 243 patients with metastatic and unresectable urothelial carcinoma were treated with either avelumab or pembrolizumab at the Yamaguchi University Hospital and its affiliated institutions. We retrospectively compared the oncological outcomes and adverse events by aligning patient characteristics and treatment backgrounds using propensity score matching.
RESULTS: The analysis compared 36 cases receiving avelumab maintenance therapy after chemotherapy to 49 cases where patients, after receiving 4 courses of chemotherapy including platinum-based agents without disease progression, were subsequently administered pembrolizumab as a second-line treatment following disease progression. Using propensity score matching, 27 cases from each group were selected for comparison. From the initiation of prechemotherapy to disease progression on immune checkpoint inhibitors, the median progression-free survival was 20.7 and 23.3 months in the avelumab and pembrolizumab groups, respectively, with no statistically significant difference observed (P = .358). However, avelumab tended to have a lower rate of high-dose glucocorticoid treatment compared to pembrolizumab.
CONCLUSION: Progression-free survival was similar for avelumab maintenance therapy and the sequence of continued chemotherapy followed by pembrolizumab after no disease progression at four chemotherapy courses. Avelumab may require less high-dose glucocorticoid treatment, potentially enhancing safety.
Adaptively randomized, double-blind treatment with duloxetine for 11 weeks in Phase 1. Non-remitting patients will be randomized in Phase 2 to adjunctive clonazepam or pregabalin for 8 weeks. Additionally, adults who are already treated with duloxetine for at least 6 weeks prior to screening, may enter Phase 2 and be randomized to adjunctive clonazepam or pregabalin for 8 weeks.
FIELD: medicine. ^ SUBSTANCE: what is described is a composition containing an ordered antigen pattern where antigen represents IL-1, mutein IL-1 or fragment IL-1. There is also offered a based vaccine. The compositions offered in the invention can be applied for producing vaccines for inflammatory diseases and chronic autoimmune diseases, transmittable diseases and cardiovascular diseases. ^ EFFECT: compositions effectively induce immune responses, particularly humoral immune responses; compositions are the most suitable for effective induction of autogenic immune responses. ^ 46 cl, 2 dwg, 3 tbl, 14 ex
The GC received standard ambulatory care, including routine exams and drug therapy. All patients were reassessed after the 2 month protocol.
XIAFLEX contains purified collagenase clostridium histolyticum, consisting of two microbial collagenases in a defined mass ratio, Collagenase AUX-I and Collagenase AUX-II, which are isolated and purified from the fermentation of Clostridium histolyticum bacteria.

Collagenase AUX-I is a single polypeptide chain consisting of approximately 1000 amino acids of known sequence. It has an observed molecular weight of 114 kiloDaltons (kDa). It belongs to the class I Clostridium histolyticum collagenases.

Collagenase AUX-II is a single polypeptide chain consisting of approximately 1000 amino acids of deduced sequence. It has an observed molecular weight of 113 kDa. It belongs to the class II Clostridium histolyticum collagenases.

XIAFLEX is supplied as a sterile lyophilized powder (white cake) intended for reconstitution with the supplied sterile diluent (0.3 mg/mL calcium chloride dihydrate in 0.9% sodium chloride) prior to intralesional injection into a Dupuytren’s cord or a Peyronie’s plaque.

XIAFLEX is available in single-use, glass vials containing 0.9 mg of collagenase clostridium histolyticum. Each vial also contains 0.5 mg of hydrochloric acid, 18.5 mg of sucrose, and 1.1 mg of tromethamine.
Aim 2 involves the prospective data collection of subjects undergoing brain or whole body oncologic PET/CT scans on the V600-R1. The purpose of this arm is to evaluate the data acquisition and image processing workflow.
The control group will engage in spontaneous, free play with the investigator supervising only for safety within the sensorimotor gym for 15 minutes, prior to the assessment of off-task behaviors during 10 minutes of developmentally appropriate tasks (DAT). All participants will wear the ActiGraph accelerometer to measure the intensity of physical activity reached during spontaneous, free play. Participants in the control group will participate in three sessions, one per week for three weeks. Intervention sessions will occur at three time points, one per week for three weeks. Following the spontaneous play, participants will engage in 10 minutes of developmentally appropriate tasks (DAT) lead by the same investigator. DAT will be videotaped and coded for off task behaviors using Momentary Time Sampling (MTS).
The group randomized to Pilates intervention will receive a 3-week intervention with Pilates Methods. The classes will be divided in: Warm up and stretching (10 minutes), Main part with Pilates exercises (40 minutes) and relaxation (10 minutes).
<P>PROBLEM TO BE SOLVED: To provide an organic solid particle which contains neither organic solvents nor water soluble components giving a heavy environmental load and has a narrow particle size distribution width.  <P>SOLUTION: A meltable organic solid component (A) is kneaded with a water-soluble auxiliary component (B) to form a dispersion. The auxiliary component (B) is eluted from the dispersion to give the organic solid particle containing at most 10,000 ppm (preferably 0 to around 5,000 ppm), based on the whole particle, of the water-soluble auxiliary component (B). Preferably, the particle has an average particle size of around 0.1-100 μm and a variation coefficient of the average particle size of at most 60. Further preferably, the particle has a ratio of the major axis to the minor axis (major axis/minor axis) of around 1.5/1 to 1/1.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Heparin-induced thrombocytopenia can occur with the administration of FRAGMIN. The incidence of this complication is unknown at present. In clinical practice, cases of thrombocytopenia with thrombosis, amputation and death have been observed [see Contraindications (4)]. Closely monitor thrombocytopenia of any degree.

In FRAGMIN clinical trials supporting non-cancer indications, platelet counts of <50,000/mm3 occurred in <1% of patients.

In the clinical trial of adult patients with cancer and acute symptomatic VTE treated for up to 6 months in the FRAGMIN treatment arm, platelet counts of <100,000/mm3 occurred in 13.6% of patients, including 6.5% who also had platelet counts less than 50,000/mm3. In the same clinical trial, thrombocytopenia was reported as an adverse event in 10.9% of patients in the FRAGMIN arm and 8.1% of patients in the Oral Anti-Coagulant (OAC) arm. FRAGMIN dose was decreased or interrupted in patients whose platelet counts fell below 100,000/mm3.

In the clinical trial of pediatric patients with or without cancer with acute symptomatic VTE treated for up to 3 months with FRAGMIN, platelet counts of <100,000/mm3 occurred in 37% of patients, including 21% who also had platelet counts less than 50,000/mm3. In the same clinical trial, thrombocytopenia was reported as an adverse reaction in 21% of patients. FRAGMIN dose was interrupted in patients whose platelet counts fell below 50,000/mm3.
Each participant will receive a one-off educational session as per standard/control group followed by a 12 week graded, individually tailored, pedometer driven walking programme given by a Physical Therapist. Participants will be monitored each week and provided with encouragement and advice to increase the number of steps taken each day.
Core decompression of the femoral head is a standard surgical procedure used in the early stages of the femoral head avascular necrosis (AVN) (Steinberg I to III). This study aimed to determine whether the advantages of osseoscopy-assisted core decompression using a standard arthroscopic set up in the early stages of AVN of the femoral head. Twelve hips of 12 patients who underwent osseoscopy-assisted core decompression and debridement with the diagnosis of AVN of the femoral head were reviewed between 2019 and 2021. The etiology was idiopathic in 2 patients; ten had a history of steroid use. The preoperative and postoperative first month Harris Hip Score (HHS) and visual analogue scale (VAS) were recorded. Standard X-rays, computerized tomography, and magnetic resonance imaging (MRI) were noted at preoperatively and sixth month follow-ups. In a 1-year follow-up, X-rays and MRIs were reviewed. All patients significantly improved in the VAS and HHS after the osseoscopy-assisted core decompression (P = .002). Two of the 12 patients with an initial stage of Steinberg IIC and IIB and one with Steinberg IA had a progressive femoral collapse and, therefore, had a total hip replacement at the end of the follow-up. Nine patients (75%) had satisfactory functional and radiological results in 1-year of follow-up. However, 3 patients (25%) culminated in total hip arthroplasty in a 1-year follow-up. Using an arthroscopic set up during osseoscopy-assisted core decompression surgery of the femoral head AVN has the benefits of direct visualization and accurate debridement of the involved area. The osseoscopy-assisted core decompression technique avoids excessive debridement of the healthy bone tissue adjacent to the necrotic area.
Sarcomas rarely develop in bones previously compromised by infarcts. These infarct-associated sarcomas often present as undifferentiated pleomorphic sarcomas (UPS), and their genetic characteristics are poorly understood. High-grade UPS of bone are typically treated with a combination of surgery and chemotherapy, similar to osteosarcoma. We conducted a detailed clinicopathologic and genomic analysis of 6 cases of intraosseous sarcomas arising from histologically and radiographically confirmed bone infarcts. We analyzed 523 genes for sequence-level mutations using next-generation sequencing with the TruSight Oncology 500 panel and utilized whole-genome single nucleotide polymorphism Microarray (OncoScan CNV) to detect copy number alterations and loss of heterozygosity (LOH). Genomic instability was assessed through homologous recombination deficiency (HRD) metrics, incorporating LOH, telomeric allelic imbalance, and large-scale state transitions. Fluorescence in situ hybridization and immunohistochemistry validated the findings. The cohort included 3 men and 3 women, with a median age of 70 years, and tumors located in the femur and tibia. Five of the 6 patients developed distant metastases. Treatment involved surgery and chemotherapy or immune checkpoint inhibitors. Genomic analysis revealed significant complexity and high HRD scores, ranging from 32 to 57 (with a cutoff of 32). Chromosome 12 alterations, including segmental amplification or chromothripsis, were observed in 4 cases. Notably, MDM2 amplification, confirmed by fluorescence in situ hybridization, was detected in 2 cases. Homozygous deletion of CDKN2A/B was observed in all six cases. Tumor mutational burden levels ranged from 2.4 to 7.9 mutations per megabase. Notable pathogenic mutations included H3-3A mutations (p.G35R and p.G35W), and mutations in HRAS, DNMT3A, NF2, PIK3CA, POLE, and TP53, each in one case. These results suggest that high-grade infarct-associated sarcomas of bone, whereas sharing high levels of structural variations with osteosarcoma, may exhibit potentially less frequent TP53 mutations and more common CDKN2A/B deletions. This points to the possibility that the mutation spectrum and disrupted pathways could be distinct from conventional osteosarcoma.
NEW MATERIAL:The compound of formula I [one of R<1> and R<2> is lower alkoxycarbonyl or carboxy and the other is group of formula II (n is 1-6)] and its salt. EXAMPLE:6-( Thiazol-5-ylmethyl )-5,6,7,8-tetrahydro-2-naphthalenecarboxylic acid sodium salt. USE:Remedy and preventive for ischemic diseases such as stenocardia, myocardial infraction, etc., cerebrovascular disorder, and thrombosis. It inhibits the synthesis of thromboxane A2, and its activity and selectivity are superior to those of known dazoxiben. PREPARATION:The compound of formula I wherein one of R<1> and R<2> is lower alkoxycarbonyl and the other is group of formula II can be prepared e.g. by reacting the compound of formula III (one of R<3> and R<4> is lower alkoxycarbonyl and the other is group of formula IV) with a nitrous acid ester such as tert-butyl nitrite in a solvent such as dimethyl sulfoxide.
PURPOSE:A drug effective for treating medullary leukemia, containing a human granular colony stimulation factor as an active ingredient. CONSTITUTION:A remedy for medullary leukemia (G-CSF for short) having the following physical and chemical properties as an active ingredient. Molecular weight: 19,000+ or -1,000 measured by sodium dodecyl sulfate-polyacrylamide gel electrophoresis method. Isoelectric point: having at least one of three electric points of pI 5.5+ or -0.1, pI 5.8+ or -0.1 and pI 6.1+ or -0.1. UV: having maximum absorption at 280nm and minimum absorption at 25nm. Amino acid sequence: having amino acid sequence shown by formula I from N end to 21-th residue. The human G-CSF contains a polypeptide shown by formula II (X is Leu. etc.; n is 0 or 1) or part thereof. The remedy has both increasing effects on peripheral mature neutrophil of patient of medullary leukemia and macrobiotic effects and is effective for medullary leukemia.
Provided are antibodies that specifically bind Vaccinia Virus (VV) A56 or B5 antigen. Also provided are fusion proteins and conjugates that comprise the antibodies. Pharmaceutical compositions and kits that comprise the antibodies, fusion proteins and conjugates are also provided. Aspects of the present disclosure further include methods of using the antibodies, fusion proteins and conjugates,  e.g ., for therapeutic purposes. In certain embodiments, provided are methods that comprise administering an antibody, fusion protein or conjugate of the present disclosure to an individual having cancer, wherein the individual comprises cancer cells infected with VV, and wherein the antibody, fusion protein or conjugate is targeted to the infected cancer cells by VV antigens expressed on the surface of the infected cancer cells. Aspects of the present disclosure further include methods of targeting an antibody, fusion protein, or conjugate that specifically binds an oncolytic virus (OV) antigen to cancer cells in an individual.
To provide a system used for more effective management and improvement of sleep habits.SOLUTION: Disclosed lifestyle expression system 10 includes: a reference information setting unit 11; an execution information acquisition unit 12; a differential information calculation unit 13; a music transformation unit 14; and an output unit 15. The reference information setting unit 11 sets a piece of reference information for each item as an index of lifestyle. The execution information acquisition unit 12 acquires a piece of execution information executed by a user for each of the items. The differential information calculation unit 13 calculates a piece of differential information from the reference information and the execution information. The music transformation unit 14 transforms a piece of music based on the differential information. The output unit 15 outputs the transformed music.SELECTED DRAWING: Figure 1
A woman in her mid-20s presented to an Indian tertiary care hospital with pain in her left forearm. Extensive initial investigations led to a suspected diagnosis of a peripheral nerve sheath tumour; however, the pathological investigation of the excised tumour mass revealed it to be a case of isolated intramuscular cysticercosis in the forearm. Treatment for cysticercosis was commenced and the patient made a full recovery. Isolated intramuscular cysticercosis without the involvement of other organs is a rare presentation and has only been reported in a handful of case reports. We suggest that isolated intramuscular cysticercosis be considered a differential diagnosis in patients with isolated pain in their muscles and with no other symptoms, in patients with a presentation of solitary swelling and in patients at risk of parasitic infection. In addition, we emphasise the importance of histopathological examination due to the varied presentation of cysts.